|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-3-25
|
|
pubmed:abstractText |
The notorious resistance of melanoma cells to drug treatment can be overcome by expression of a 50-aa peptide derived from activating transcription factor 2 (ATF2(50-100)). Here we demonstrate that ATF2(50-100) induced apoptosis by sequestering ATF2 to the cytoplasm, thereby inhibiting its transcriptional activities. Furthermore, ATF2(50-100) binds to c-Jun N-terminal kinase (JNK) and increases its activity. Mutation within ATF2(50-100) that impairs association with JNK and the inhibition of JNK or c-Jun expression by RNA interference (RNAi) reduces the degree of ATF2(50-100)-induced apoptosis. In contrast, TAM67, a dominant negative of the Jun family of transcription factors, or JunD RNAi attenuates sensitization of melanoma cells expressing ATF2(50-100) to apoptosis after treatment with anisomycin, which is used as a model drug. Mutations within the JNK binding region of ATF2(50-100) or expression of TAM67 or JunD RNAi attenuates inhibition of melanoma's tumorigenicity by ATF2(50-100). We conclude that inhibition of ATF2 in concert with increased JNK/Jun and JunD activities is central for the sensitization of melanoma cells to apoptosis and inhibition of their tumorigenicity.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-10318823,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-10702802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-10754286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-10848607,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-11106750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-11196646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-11259409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-11287623,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-11463377,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-11526502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12068308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12086670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12110590,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12208865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12226747,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12235125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12242156,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12594806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12633838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12724420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12789290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12789291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12820962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12821943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-12853483,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-14678960,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-1641004,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-7540859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-7692236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-7824938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-8355695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-8875991,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-9130714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-9484842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-9770464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-9802983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15010535-9933637
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ATF2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Activating Transcription Factor 2,
http://linkedlifedata.com/resource/pubmed/chemical/Atf2 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP Response...,
http://linkedlifedata.com/resource/pubmed/chemical/JNK Mitogen-Activated Protein...,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-jun,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
23
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4222-7
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15010535-Activating Transcription Factor 2,
pubmed-meshheading:15010535-Animals,
pubmed-meshheading:15010535-Apoptosis,
pubmed-meshheading:15010535-Cyclic AMP Response Element-Binding Protein,
pubmed-meshheading:15010535-Cytoplasm,
pubmed-meshheading:15010535-Humans,
pubmed-meshheading:15010535-JNK Mitogen-Activated Protein Kinases,
pubmed-meshheading:15010535-Melanoma,
pubmed-meshheading:15010535-Mice,
pubmed-meshheading:15010535-Mitogen-Activated Protein Kinases,
pubmed-meshheading:15010535-Mutation,
pubmed-meshheading:15010535-Peptides,
pubmed-meshheading:15010535-Proto-Oncogene Proteins c-jun,
pubmed-meshheading:15010535-Transcription Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity.
|
|
pubmed:affiliation |
Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
